Stay updated on Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.

Latest updates to the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was applied with update dates (2026-02-05, 2026-02-03, 2026-02). A funding-lapse notice was removed from the page.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a general notice about government funding lapse and NIH Clinical Center status, and updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedUI and metadata updates including a new glossary toggle and revised QC-related labels and revision/version notes; these changes do not affect core trial data, eligibility criteria, or study results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 is now shown instead of v3.3.3; no changes to the study details or page behavior were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a consolidated Locations section listing Florida, Maryland, and New York sites. Removed the prior state-specific location subsections; page revision updated to v3.3.3.SummaryDifference0.4%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the ClinicalTrials.gov page. No substantive changes to the study details are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.